CoChat

Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration

Open access
Sahaboglu, Ayse, Barth, Melanie, Secer, Enver, Amo, Eva M. del, Urtti, Arto, Arsenijevic, Yvan, Zrenner, Eberhart, Paquet-Durand, François · 2016 · Scientific Reports

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

The enzyme poly-ADP-ribose-polymerase (PARP) mediates DNA-repair and rearrangements of the nuclear chromatin. Generally, PARP activity is thought to promote cell survival and in recent years a number of PARP inhibitors have been clinically developed for cancer treatment. Paradoxically, PARP activity is also connected to many diseases including the untreatable blinding disease Retinitis Pigmentosa (RP), where PARP activity appears to drive the pathogenesis of photoreceptor loss. We tested the efficacy of three different PARP inhibitors to prevent photoreceptor loss in the rd1 mouse model for RP. In retinal explant cultures in vitro, olaparib had strong and long-lasting photoreceptor neuroprotective capacities. We demonstrated target engagement by showing that olaparib reduced photoreceptor accumulation of poly-ADP-ribosylated proteins. Remarkably, olaparib also reduced accumulation of cyclic-guanosine-monophosphate (cGMP), a characteristic marker for photoreceptor degeneration. Moreover, intravitreal injection of olaparib in rd1 animals diminished PARP activity and increased photoreceptor survival, confirming in vivo neuroprotection. This study affirms the role of PARP in inherited retinal degeneration and for the first time shows that a clinically approved PARP inhibitor can prevent photoreceptor degeneration in an RP model. The wealth of human clinical data available for olaparib highlights its strong potential for a rapid clinical translation into a novel RP treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep39537

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Olaparib rescues rd1 photoreceptors in short-term retinal explant cultures. (a) Immunohistochemical staining revealed a dose-dependent effect of olaparib treatment with 100 nM as the most protective concentration and toxic effects of high concentrations. (b) Quantification of photoreceptor rows. (c) Quantification of the percentage of TUNEL positive cells. Bar graphs represent means ± SEM. n(wt, untreated) = 6; n(wt, 0.1 μM olaparib) = 6; n(rd1, untreated) = 9; n(rd1, 0.01 μM olaparib) = 5; n(rd1, 0.1 μM olaparib) = 9; n(rd1, 1 μM olaparib) = 7; n(rd1, 10 μM olaparib) = 7; n(rd1, 20 μM olaparib) = 4; n(rd1, 50 μM olaparib) = 6. **p < 0.01 by Kruskal-Wallis test for multiple analysis; scale bar is 20 μm.
Figure 1 Olaparib rescues rd1 photoreceptors in short-term retinal explant cultures. (a) Immunohistochemical staining revealed a dose-dependent effect of olaparib treatment with 100 nM as the most protective concentration and toxic effects of high concentrations. (b) Quantification of photoreceptor rows. (c) Quantification of the percentage of TUNEL positive cells. Bar graphs represent means ± SEM. n(wt, untreated) = 6; n(wt, 0.1 μM olaparib) = 6; n(rd1, untreated) = 9; n(rd1, 0.01 μM olaparib) = 5; n(rd1, 0.1 μM olaparib) = 9; n(rd1, 1 μM olaparib) = 7; n(rd1, 10 μM olaparib) = 7; n(rd1, 20 μM olaparib) = 4; n(rd1, 50 μM olaparib) = 6. **p < 0.01 by Kruskal-Wallis test for multiple analysis; scale bar is 20 μm.CC BY · PubMed Central
Figure 2 Effect of PARP inhibition with olaparib on PARylation and cGMP levels in rd1 retinal cultures. (a,b) The higher the concentration of olaparib, the smaller was the percentage of PAR positive cells. (c) Western blot analysis confirmed the previously reported strong PARylation difference between rd1 and wildtype (wt) retinas89. Furthermore, there was a strong reduction of PARylation in rd1 cultures treated with 100 nM olaparib compared to control cultures. (d) Immunohistochemical stainings showed an increase of cGMP level in rd1 compared to wt. (e) Quantification of the cGMP signal revealed a significant reduction due to treatment with olaparib. Bar graphs represent means ± SEM. n(wt, untreated) = 6; n(wt, 0.1 μM olaparib) = 6; n(rd1, untreated) = 9; n(rd1, 0.01 μM olaparib) = 5; n(rd1, 0.1 μM olaparib) = 9; n(rd1, 1 μM olaparib) = 7; n(rd1, 10 μM olaparib) = 7; n(rd1, 20 μM olaparib) = 4; n(rd1, 50 μM olaparib) = 6; n(WB, in vivo, rd1) = 1; n(WB, in vivo, wt) = 1; n(WB, in vitro, rd1, untreated) = 3; n(WB, in vitro, rd1, olaparib) = 3. **p < 0.01 by Kruskal-Wallis test for multiple analysis; scale bars in (a and d) are 20 μm.
Figure 2 Effect of PARP inhibition with olaparib on PARylation and cGMP levels in rd1 retinal cultures. (a,b) The higher the concentration of olaparib, the smaller was the percentage of PAR positive cells. (c) Western blot analysis confirmed the previously reported strong PARylation difference between rd1 and wildtype (wt) retinas89. Furthermore, there was a strong reduction of PARylation in rd1 cultures treated with 100 nM olaparib compared to control cultures. (d) Immunohistochemical stainings showed an increase of cGMP level in rd1 compared to wt. (e) Quantification of the cGMP signal revealed a significant reduction due to treatment with olaparib. Bar graphs represent means ± SEM. n(wt, untreated) = 6; n(wt, 0.1 μM olaparib) = 6; n(rd1, untreated) = 9; n(rd1, 0.01 μM olaparib) = 5; n(rd1, 0.1 μM olaparib) = 9; n(rd1, 1 μM olaparib) = 7; n(rd1, 10 μM olaparib) = 7; n(rd1, 20 μM olaparib) = 4; n(rd1, 50 μM olaparib) = 6; n(WB, in vivo, rd1) = 1; n(WB, in vivo, wt) = 1; n(WB, in vitro, rd1, untreated) = 3; n(WB, in vitro, rd1, olaparib) = 3. **p < 0.01 by Kruskal-Wallis test for multiple analysis; scale bars in (a and d) are 20 μm.CC BY · PubMed Central
Figure 3 Long-term protective effects of olaparib treatment in rd1TN-XL retinal cultures at P17. (a) Immunohistochemical staining, at P17, showed improved photoreceptor viability in 0.1 μM olaparib treated cultures, when compared to untreated (untr.) control. (b) The number of photoreceptor rows was significantly increased after treatment. (c) There were less TUNEL positive cells in olaparib-treated cultures. (d) Cone density (EGFP signal) remained unchanged after treatment. Bar graphs represent means ± SEM. n(rd1, untreated) = 5; n(rd1, 0.1 μM olaparib) = 5. **p < 0.01 by two-sample Komolgorov-Smirnov test; scale bar is 20 μm.
Figure 3 Long-term protective effects of olaparib treatment in rd1TN-XL retinal cultures at P17. (a) Immunohistochemical staining, at P17, showed improved photoreceptor viability in 0.1 μM olaparib treated cultures, when compared to untreated (untr.) control. (b) The number of photoreceptor rows was significantly increased after treatment. (c) There were less TUNEL positive cells in olaparib-treated cultures. (d) Cone density (EGFP signal) remained unchanged after treatment. Bar graphs represent means ± SEM. n(rd1, untreated) = 5; n(rd1, 0.1 μM olaparib) = 5. **p < 0.01 by two-sample Komolgorov-Smirnov test; scale bar is 20 μm.CC BY · PubMed Central
Figure 4 Olaparib does not affect increased DNA methylation. (a) Co-localization of TUNEL, 5mC, and 5hmC on rd1 retina at P13. (b) Of the TUNEL positive cells (n = 69), about half were also 5mC positive and nearly all cells were 5hmC positive. All 5mC positive cells (n = 29) were also TUNEL positive, whereas of all 5hmC positive cells (n = 57), there was a small fraction (n = 6) that did not show TUNEL signal. (c) Quantification of co-localization, in rows, e.g. of all TUNEL positive cells 50.6 ± 11.4 were 5mC and 72.2 ± 4.7 were 5hmC positive. (d) Immunohistochemical staining showed an increase of both 5mC and 5hmC levels in rd1 retinal cultures compared to wildtype (wt). (e) Quantification of histological methylation signal. In rd1 cultures there was no significant reduction after treatment with olaparib (5mC: p = 0.3517; 5hmC: p = 0.7858). Bar graphs represent means ± SEM. n(rd1 P13) = 4; n(wt, untreated) = 6; n(wt, olaparib) = 6; n(rd1, untreated) = 10; n(rd1, olaparib) = 8. Tested by two-sample Komolgorov-Smirnov test. Scale bars in (a and d) are 20 μm.
Figure 4 Olaparib does not affect increased DNA methylation. (a) Co-localization of TUNEL, 5mC, and 5hmC on rd1 retina at P13. (b) Of the TUNEL positive cells (n = 69), about half were also 5mC positive and nearly all cells were 5hmC positive. All 5mC positive cells (n = 29) were also TUNEL positive, whereas of all 5hmC positive cells (n = 57), there was a small fraction (n = 6) that did not show TUNEL signal. (c) Quantification of co-localization, in rows, e.g. of all TUNEL positive cells 50.6 ± 11.4 were 5mC and 72.2 ± 4.7 were 5hmC positive. (d) Immunohistochemical staining showed an increase of both 5mC and 5hmC levels in rd1 retinal cultures compared to wildtype (wt). (e) Quantification of histological methylation signal. In rd1 cultures there was no significant reduction after treatment with olaparib (5mC: p = 0.3517; 5hmC: p = 0.7858). Bar graphs represent means ± SEM. n(rd1 P13) = 4; n(wt, untreated) = 6; n(wt, olaparib) = 6; n(rd1, untreated) = 10; n(rd1, olaparib) = 8. Tested by two-sample Komolgorov-Smirnov test. Scale bars in (a and d) are 20 μm.CC BY · PubMed Central
Figure 5 Olaparib protects rd1 photoreceptors in vivo. After a single intravitreal olaparib injection at P11 rd1 animals where analyzed for cell death (TUNEL assay) and photoreceptor survival at P13 and P15. (a) Retinas from sham-injected rd1 animals display a high number of dying, TUNEL positive cells in the ONL. At P13, in treated animals cell death is reduced, an effect that is still apparent at P15. Note the decrease in the overall size of the rd1 ONL and the number of photoreceptor rows at P15. (b) A subset of rd1 photoreceptors showed a strong immunoreactivity for PARylated proteins, their numbers appeared lower in P13 and P15 treated animals. (c) Top panel: Quantification of TUNEL positive cells in untreated vs. treated animals at P13 and P15. At P13 there were significantly less photoreceptors dying in treated rd1 retina. Bottom panel: Quantification of PAR positive cells in untreated vs. treated animals at P13 and P15. (d) Quantitative analysis of photoreceptor survival along the dorso-ventral axis. While untreated P15 rd1 retina displayed 3-6 photoreceptor rows, olaparib treated rd1 animals had up to two rows more photoreceptors in the mid-periphery, dorsal retina. n(rd1, sham-injected P13) = 6; n(rd1, treated P13) = 5; n(rd1, sham-injected P15) = 4; n(rd1, untreated P15) = 5. Tested by unpaired, two-tailed Student’s t-test. Scale bars in (a and b) are 50 μm.
Figure 5 Olaparib protects rd1 photoreceptors in vivo. After a single intravitreal olaparib injection at P11 rd1 animals where analyzed for cell death (TUNEL assay) and photoreceptor survival at P13 and P15. (a) Retinas from sham-injected rd1 animals display a high number of dying, TUNEL positive cells in the ONL. At P13, in treated animals cell death is reduced, an effect that is still apparent at P15. Note the decrease in the overall size of the rd1 ONL and the number of photoreceptor rows at P15. (b) A subset of rd1 photoreceptors showed a strong immunoreactivity for PARylated proteins, their numbers appeared lower in P13 and P15 treated animals. (c) Top panel: Quantification of TUNEL positive cells in untreated vs. treated animals at P13 and P15. At P13 there were significantly less photoreceptors dying in treated rd1 retina. Bottom panel: Quantification of PAR positive cells in untreated vs. treated animals at P13 and P15. (d) Quantitative analysis of photoreceptor survival along the dorso-ventral axis. While untreated P15 rd1 retina displayed 3-6 photoreceptor rows, olaparib treated rd1 animals had up to two rows more photoreceptors in the mid-periphery, dorsal retina. n(rd1, sham-injected P13) = 6; n(rd1, treated P13) = 5; n(rd1, sham-injected P15) = 4; n(rd1, untreated P15) = 5. Tested by unpaired, two-tailed Student’s t-test. Scale bars in (a and b) are 50 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Research works printed but not linked: 1

  1. Wei, T. et al. Generation and functional characterization of a transgenic mouse expressing a Ca2+ biosensor in cone photoreceptors. J. Neurosci. 32, 6994–6981 (2012).

Cited by

Metadata

Authors
Sahaboglu, A., Barth, M., Secer, E., Amo, E. M. D., Urtti, A., Arsenijevic, Y., Zrenner, E., & Paquet-Durand, F.
Affiliations
  • University of Tübingen (DE)
  • University of Eastern Finland (FI)
  • University of Helsinki (FI)
Corresponding author
Sahaboglu, Ayse
Venue
Scientific Reports
Published
2016-12-22
Volume
6
Issue
1
Pages
39537-39537
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2561847233
Cited by
53
References
45
Citations by year
2026: 1 · 2025: 9 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 10 · 2020: 3 · 2019: 12 · 2018: 3 · 2017: 1
FWCI
2.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by)
  • SERVAL (Université de Lausanne) (publishedVersion, other-oa)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • IRIS (submittedVersion)
Funders
  • European Commission (304963)
  • Deutsche Forschungsgemeinschaft (PA1751/7‐1, HEALTH-F2-2012-304963, SA3040/1-1)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
olaparib, PARP inhibitors, retinitis pigmentosa, photoreceptor degeneration, rd1 mouse model, inherited retinal degeneration, poly(ADP-ribosyl)ation, cyclic GMP, intravitreal injection, retinal explant culture, DNA repair
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Animals, Cell Survival, Chromatin, Cyclic GMP, Immunohistochemistry, Mice, Inbred C3H, Neoplasms, Phthalazines, Piperazines, Poly(ADP-ribose) Polymerases, Protein Binding, Rabbits, Retinal Degeneration, Neuroprotective Agents, Photoreceptor Cells, Vertebrate, Quantitative Structure-Activity Relationship, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.